Table 1:
Demographic and Clinical Characteristics of the Study Participants
| Characteristics | Survivor (n=630) | Sibling (n=289) | P-value |
|---|---|---|---|
| Age at aBMT (years, mean ± SD) | 57.6 ± 8.5 | NA | |
| Interval between aBMT and survey (mean, years± SD) | 6.6 ± 3.7 | NA | |
| Age at survey (mean, years± SD) | 64.2 ± 7.9 | 64.0 ± 8.1 | 0.7 |
| Sex n (%) | |||
| Female | 265 (42.1) | 122 (42.2) | 1.0 |
| Race and Ethnicity n (%) | |||
| White | 393 (62.2) | 244 (84.4) | <0.001 |
| Hispanic | 109 (17.3) | 18 (6.2) | |
| Black | 87 (13.8) | 9 (3.1) | |
| Asian | 21 (3.3) | 14 (4.8) | |
| Mixed/other/unknown | 21 (3.3) | 4 (1.4) | |
| Education n (%) | |||
| <High school | 42 (6.7) | 5 (1.7) | 0.0001 |
| High school and some college | 311 (49.4) | 121 (41.9) | |
| College graduate and post-graduate | 276 (43.8) | 163 (56.4) | |
| Missing | 1 (0.16) | 0 (0.00) | |
| Annual household income n (%) | |||
| < $50,000 | 188 (29.8) | 49 (16.7) | <0.001 |
| $50,000-$100,000 | 205 (32.5) | 89 (30.8) | |
| >$100,000 | 148 (23.5) | 120 (41.5) | |
| Missing | 89 (14.1) | 31 (10.7) | |
| Current insurance n (%) | |||
| Yes | 625 (99.2) | 288 (99.7) | 0.4 |
| Conditioning n (%) | |||
| Cyclophosphamide | 40 (7.60) | NA | |
| Melphalan | 517 (98.3) | NA | |
| TBI | 29 (5.5) | NA | |
| Other | 38 (7.2) | NA | |
| Missing | 104 | NA | |
| Therapeutic exposures pre-aBMT n (%) | |||
| Cyclophosphamide | 78 (15.1) | NA | |
| Melphalan | 25 (4.8) | NA | |
| Steroids | 512 (99) | NA | |
| Doxorubicin | 113 (21.9) | NA | |
| Bortezomib | 270 (52.2) | NA | |
| Vincristine | 93 (18) | NA | |
| IMiD (Thalidomide or lenalidomide) | 330 (63.8) | NA | |
| Radiation therapy | 120 (23.2) | NA | |
| Other | 20 (3.9) | NA | |
| Missing | 113 | NA | |
| Grade 3–4 Chronic Health Conditions | |||
| Yes | 273 (43.3) | 107 (37) | 0.07 |
Abbreviations: TBI: total body radiation, IMiD: Immunomodulatory drugs